Learn more about our very first Myeloma UK Infoday designed exclusively for carers, family and friends of myeloma patients, which received outstanding feedback from attendees.
Our Health Services Research Manager, Dr Jayne Galinsky, talks about presenting Myeloma UK’s research on patient treatment preferences at two major clinical conferences held recently in Rome and Madrid.
Discover how Myeloma UK is working in partnership with a group of key myeloma and healthcare professionals to improve diagnosis rates for myeloma patients.
Myeloma Awareness Week 2017 focuses is on early diagnosis because for patients, every day counts. Here’s how you can get involved!
An experienced and accomplished healthcare leader has been appointed Chief Executive of Myeloma UK. Rosemarie Finley is joining Myeloma UK from the Epilepsy Society, where she was Acting Chief Executive and Chief Operating Officer. She has more than 30 years of management experience in the healthcare sector. A trained nurse, she held a number of senior leadership positions at Buckinghamshire Healthcare NHS Trust…
Carfilzomib (Kyprolis®) has been approved for use on the NHS in England and Wales in combination with dexamethasone by drug approval body, the National Institute for Health and Care Excellence (NICE). The approval applies only to myeloma patients who have had one prior treatment, as long as that treatment did not include bortezomib, which is also known as Velcade®.
This year’s Myeloma UK London Paris Ride saw 137 people including myeloma patients and their friends and family, doctors and […]
A new survey being funded by Myeloma UK and carried out by the National Institute for Health and Care Excellence […]
Myeloma UK has launched a new type of Infoday designed exclusively to support the carers, family and friends of myeloma […]
Myeloma UK has launched a new Infopack to provide relapsed and/or refractory patients and their families with the information they […]